Full-Time

Principal Scientist

Molecular Biology

Posted on 8/17/2024

Generation Bio

Generation Bio

51-200 employees

Develops durable genetic treatments for diseases

Biotechnology
Healthcare

Senior

Cambridge, MA, USA

Headquartered in Cambridge, Massachusetts.

Category
Genomics
Biology Lab & Research
Biology & Biotech
Requirements
  • PhD in Molecular Biology, Cell Biology, Synthetic biology, Bioengineering, Biochemistry or related discipline.
  • Minimum of 6 years of relevant experience, majority in an industry setting.
  • Experience in scientific fields of nuclear pore complex structure/ function, cellular trafficking of diverse cargos, mechanism of mRNA export, viral packaging and nuclear translocation, or related field.
  • Capacity for innovative thinking and critical problem solving.
  • Excellent communication and interpersonal skills with capacity and proven track record of working cross functionally.
Responsibilities
  • Lead design approaches for optimizing nuclear translocation of nucleic acid cargoes.
  • Generate appropriately scoped research plans to meet scientific and resourcing demands.
  • Lead execution of research individually and as part of function and cross functional teams.
  • Present scientific ideas and results effectively to different teams and groups within the organization.
  • Accountable for on-time execution of experimental projects to advance our iqDNA platform.

Generation Bio focuses on developing genetic treatments for both rare and common diseases. Their main product is based on a non-viral genetic medicine platform that includes iqDNA, which is designed to be immune-quiet, and ctLNP, a delivery system that targets specific cells. This technology allows for the delivery of large amounts of genetic material to particular tissues, aiming for long-lasting effects from a single dose. They use a unique manufacturing process called rapid enzymatic synthesis (RES) that enables them to produce these treatments at scale, potentially reaching hundreds of millions of doses. Unlike many competitors, Generation Bio's approach allows for redosing, meaning that treatments can be adjusted over time to meet patient needs. The company's goal is to make genetic medicine more accessible and to address significant medical needs in the population.

Company Stage

IPO

Total Funding

$252.9M

Headquarters

Cambridge, Massachusetts

Founded

2016

Growth & Insights
Headcount

6 month growth

1%

1 year growth

-21%

2 year growth

-14%
Simplify Jobs

Simplify's Take

What believers are saying

  • Strategic collaboration with Moderna boosts development and market entry potential.
  • Non-viral platform aligns with safety trends, increasing demand for Generation Bio's tech.
  • Reorganization extends cash runway, supporting long-term sustainability and investor confidence.

What critics are saying

  • 40% workforce reduction may impact innovation and strategic execution.
  • Lease termination could lead to legal or financial distractions.
  • Financial constraints might limit future R&D investments.

What makes Generation Bio unique

  • Generation Bio's iqDNA evades immune detection, unlike traditional gene therapies.
  • Their ctLNP system offers targeted delivery, enhancing treatment precision.
  • RES manufacturing allows scalable production, supporting broad treatment access.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE